Literature DB >> 22902549

HCV NS5A and IRF9 compete for CypA binding.

Michael Bobardt1, Sam Hopkins, James Baugh, Udayan Chatterji, Felicia Hernandez, John Hiscott, Ann Sluder, Kai Lin, Philippe A Gallay.   

Abstract

BACKGROUND & AIMS: Cyclophilin A (CypA) is vital for HCV replication. Cyp inhibitors successfully decrease viral loads in HCV-infected patients. However, their mechanisms of action remain unknown. Since interferon (IFN) can also suppress HCV replication, we asked whether a link between CypA and the IFN response exists.
METHODS: We used cellular and recombinant pulldown approaches to investigate the possibility of a specific association of CypA with host ligands.
RESULTS: We found for the first time that CypA binds to a major component of the IFN response - the IFN regulatory factor 9 (IRF9). IRF9 is the DNA-binding component of the transcriptional IFN-stimulated gene factor 3 (ISGF3). CypA binds directly to IRF9 via its peptidyl-prolyl isomerase (PPIase) pocket. Cyp inhibitors such as cyclosporine A (CsA) or non-immunosuppressive derivates such as alisporivir and SCY-635, prevent IRF9-CypA complex formation. CypA binds to the C-terminal IRF-association-domain (IAD), but not to the DNA-binding or linker domains of IRF9. Remarkably, CypA associates with the multimeric ISGF3 complex. We also obtained evidence that CypA neutralization enhances IFN-induced transcription. Interestingly, the hepatitis C virus (HCV) non-structural 5A (NS5A) protein, which is known to modulate the IFN response, competes with IRF9 for CypA binding and can prevent the formation of IRF9-CypA complexes.
CONCLUSIONS: This study demonstrates for the first time that CypA binds specifically to a component of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, IRF9. This study also reveals a novel opportunity of HCV to modulate the IFN response via NS5A.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22902549      PMCID: PMC3527675          DOI: 10.1016/j.jhep.2012.08.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  51 in total

1.  Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7.

Authors:  R Lin; P Génin; Y Mamane; J Hiscott
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

2.  ISGF3, the transcriptional activator induced by interferon alpha, consists of multiple interacting polypeptide chains.

Authors:  X Y Fu; D S Kessler; S A Veals; D E Levy; J E Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 3.  Stealth and cunning: hepatitis B and hepatitis C viruses.

Authors:  Stefan F Wieland; Francis V Chisari
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 4.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

5.  Update on alisporivir in treatment of viral hepatitis C.

Authors:  Robert Flisiak; Jerzy Jaroszewicz; Iwona Flisiak; Tadeusz Łapiński
Journal:  Expert Opin Investig Drugs       Date:  2012-02-08       Impact factor: 6.206

Review 6.  The growing family of interferon regulatory factors.

Authors:  H Nguyen; J Hiscott; P M Pitha
Journal:  Cytokine Growth Factor Rev       Date:  1997-12       Impact factor: 7.638

7.  Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy.

Authors:  Eric Lawitz; Eliot Godofsky; Regine Rouzier; Thomas Marbury; Tuan Nguyen; June Ke; MeiMei Huang; Jens Praestgaard; Denise Serra; Thomas G Evans
Journal:  Antiviral Res       Date:  2011-01-19       Impact factor: 5.970

8.  Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. I. Taxonomy, fermentation, isolation and biological activity.

Authors:  J J Sanglier; V Quesniaux; T Fehr; H Hofmann; M Mahnke; K Memmert; W Schuler; G Zenke; L Gschwind; C Maurer; W Schilling
Journal:  J Antibiot (Tokyo)       Date:  1999-05       Impact factor: 2.649

9.  A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells.

Authors:  Nicolas Manel; Brandon Hogstad; Yaming Wang; David E Levy; Derya Unutmaz; Dan R Littman
Journal:  Nature       Date:  2010-09-09       Impact factor: 49.962

10.  Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B.

Authors:  Fiona Fernandes; Daniel S Poole; Spencer Hoover; Rannveig Middleton; Adin-Cristian Andrei; Justin Gerstner; Rob Striker
Journal:  Hepatology       Date:  2007-10       Impact factor: 17.425

View more
  11 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

2.  Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Authors:  David R McGivern; Takahiro Masaki; Sara Williford; Paul Ingravallo; Zongdi Feng; Frederick Lahser; Ernest Asante-Appiah; Petra Neddermann; Raffaele De Francesco; Anita Y Howe; Stanley M Lemon
Journal:  Gastroenterology       Date:  2014-04-22       Impact factor: 22.682

3.  Cyclophilin A Inhibits Human Respiratory Syncytial Virus (RSV) Replication by Binding to RSV-N through Its PPIase Activity.

Authors:  Wenzhang Liang; Yue Zhang; Miao Li; Fadhl Al-Shaebi; Jian Li; Jing Zhang; Lin Wei
Journal:  J Virol       Date:  2021-07-12       Impact factor: 5.103

Review 4.  Cyclophilins as modulators of viral replication.

Authors:  Stephen D Frausto; Emily Lee; Hengli Tang
Journal:  Viruses       Date:  2013-07-11       Impact factor: 5.048

5.  Bioengineering and semisynthesis of an optimized cyclophilin inhibitor for treatment of chronic viral infection.

Authors:  Magnus Joakim Hansson; Steven James Moss; Michael Bobardt; Udayan Chatterji; Nigel Coates; Jose A Garcia-Rivera; Eskil Elmér; Steve Kendrew; Pieter Leyssen; Johan Neyts; Mohammad Nur-E-Alam; Tony Warneck; Barrie Wilkinson; Philippe Gallay; Matthew Alan Gregory
Journal:  Chem Biol       Date:  2015-01-22

Review 6.  Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection.

Authors:  Ana Maria Ortega-Prieto; Marcus Dorner
Journal:  Vaccines (Basel)       Date:  2017-09-01

Review 7.  Profile of alisporivir and its potential in the treatment of hepatitis C.

Authors:  Philippe A Gallay; Kai Lin
Journal:  Drug Des Devel Ther       Date:  2013-02-15       Impact factor: 4.162

8.  Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Authors:  Fredrik Holmström; Margaret Chen; Anangi Balasiddaiah; Matti Sällberg; Gustaf Ahlén; Lars Frelin
Journal:  Sci Rep       Date:  2016-05-04       Impact factor: 4.379

9.  Classical swine fever virus NS5A protein changed inflammatory cytokine secretion in porcine alveolar macrophages by inhibiting the NF-κB signaling pathway.

Authors:  Xiao-Ying Dong; Sheng-Qiu Tang
Journal:  Virol J       Date:  2016-06-14       Impact factor: 4.099

Review 10.  Interferon Regulatory Factor 9 Structure and Regulation.

Authors:  Alvin Paul; Thean Hock Tang; Siew Kit Ng
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.